CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86

Nature Immunology

Volumn 5, Issue 11, 2004, Pages 1134-1142

  Orabona, Ciriana ^a   Grohmann, Ursula ^a   Belladonna, Maria Laura ^a   Fallarino, Francesca ^a   Vacca, Carmine ^a   Bianchi, Roberta ^a   Bozza, Silvia ^a   Volpi, Claudia ^a   Salomon, Benoît L ^b   Fioretti, Maria Cristina ^a   Romani, Luigina ^a   Puccetti, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G3; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE P38; TRYPTOPHAN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANDIDA ALBICANS; CANDIDIASIS; CATABOLISM; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; EFFECTOR CELL; EXPERIMENTAL NEOPLASM; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VIVO STUDY; MALE; MICROBIAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; CANDIDIASIS; DENDRITIC CELLS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 9244231842     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1124     Document Type: Article

References (54)

1. Schwartz, R.H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1068 (1992).
2. Lenschow, D.J., Walunas, T.L. & Bluestone, J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
3. Egen, J.G., Kuhns, M.S. & Allison, J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
4. Acuto, O. & Michel, F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3 939-951 (2003).
5. Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612 (1993).
6. -/- mice. J. Immunol. 157, 4822-4829 (1996).
7. Salomon, B. & Bluestone, J.A. Complexities of CD28/87: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
8. Sansom, D.M., Manzotti, C.N. & Zheng, Y. What's the difference between CD80 and CD86? Trends Immunol. 24, 314-319 (2003).
9. Lohr, J., Knoechel, B., Jiang, S., Sharpe, A.H. & Abbas, A.K. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat. Immunol. 4, 664-669 (2003).
10. Fallarino, F., Fields, P.E. & Gajewski, T.F B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 188, 205-210 (1998).
11. Thompson, C.B. & Allison, J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7, 445-450 (1997).
12. Oosterwegel, M.A., Greenwald, R.J., Mandelbrot, D.A., Lorsbach, R.B. & Sharpe, A.H. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11, 294-300 (1999).
13. Alegre, M.L., Frauwirth, K.A. & Thompson, C.B. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1, 220-228 (2001).
14. Finger, E.B. & Bluestone, J.A. When ligand becomes receptor - tolerance via B7 signaling on DCs. Nat. Immunol. 3, 1056-1057 (2002).
15. Grohmann, U. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3, 1097-1101 (2002).
16. Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212 (2003).
17. Grohmann, U., Fallarino, F. & Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
18. Linsley, P.S. et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173, 721-730 (1991).
19. Lanier, L.L. et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154, 97-105 (1995).
20. + dendritic cells expressing indoleamine 2,3-dioxygenase. J. Immunol. 167, 708-714 (2001).
21. Mann, J., Oakley, F., Johnson, P.W. & Mann, D.A. CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-κB, and CBF1. J. Biol. Chem. 277, 17125-17138 (2002).
22. Saccani, S., Pantano, S. & Natoli, G. Two waves of nuclear factor κB recruitment to target promoters. J. Exp. Med. 193, 1351-1359 (2001).
23. Saccani, S., Pantano, S. & Natoli, G. p38-Dependent marking of inflammatory genes for increased NF-κB recruitment. Nat. Immunol. 3, 69-75 (2002).
24. Grohmann, U. et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J. Immunol. 166, 277-283 (2001).
25. Grohmann, U. et al. Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J. Immunol. 171, 2581-2587 (2003).
26. Croker, B.A. et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 (2003).
27. Lang, R. et al. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4, 546-550 (2003).
28. Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4 551-556 (2003).
29. Johnston, J.A. & O'Shea, J.J. Matching SOCS with function. Nat. Immunol. 4, 507-509 (2003).
30. Shortman, K. & Heath, W.R. Immunity or tolerance? That is the question for dendritic cells. Nat. Immunol. 2, 988-989 (2001).
31. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274 (2003).
32. Amrani, A. et al. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406 739-742 (2000).
33. Medzhitov, R. & Janeway, C. Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89-97 (2000).
34. Puccetti, P., Romani, L. & Bistoni, F. A TH1-TH2-like switch A candidiasis: new perspectives for therapy. Trends Microbiol. 3 237-240 (1995).
35. Romani, L. Immunity to fungal infections. Nat. Rev. Immunol. 4, 1-23 (2004).
36. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183, 1345-1355 (1996).
37. d'Ostiani, C.F. et al. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J. Exp. Med. 191, 1661-1674 (2000).
38. + T cell-dependent tumor eradication in vivo. J. Immunol. 165, 5495-5501 (2000).
39. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
40. Yang, Y., Huang, C.-T., Huang, X. & Pardoll, D.M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5, 508-515 (2004).
41. Rothstein, D.M. & Sayegh, M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196, 85-108 (2003).
42. Azzi, M. β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 100, 11406-11411 (2003).
43. Andres, P.G. et al. Distinct regions in the CD2B cytoplasmic domain are required for T helper type 2 differentiation. Nat Immunol. 5, 435-442 (2004).
44. Chen, C.Y., Cordeaux, Y., Hill, S.J. & King, J.R. Modelling of signalling via G-protein coupled receptors: pathway-dependent agonist potency and efficacy. Bull. Math. Biol. 65, 933-958 (2003).
45. + regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J. Exp. Med. 199 25-34 (2004).
46. Bour-Jordan, H. & Bluestone, J.A. CD28 function; a balance of costimulatory and regulatory signals. J. Clin. Immunol. 22, 1-7 (2002).
47. + T cells. Immunity 19, 877-889 (2003).
48. + regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J. Immunol. 169, 6298-6308 (2002).
49. Bellocchio, S. et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol. 172, 3059-3069 (2004 ).
50. Belladonna, M.L. et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168, 5448-5454 (2002).
51. Gajewski, T.F., Fallarino, F., Uyttenhove, C. & Boon, T. Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156, 2909-2917 (1996).
52. + subset. J. Immunol. 165, 1357-1363 (2000).
53. Richard, M., Louahed, J., Demoulin, J.B. & Renauld, J.C. Interleukin-9 regulates NF-κB activity through BCL3 gene induction. Blood 93, 4318-4327. (1999).
54. - or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur. J. Immunol. 25, 2797-2802 (1995).